Emerald Health Pharmaceuticals; a biotech company entering Phase 2 human studies with patented unique cannabinoid science & technology focused on diseases like multiple sclerosis and Parkinson's disease; 180+ yrs mgt-team experience; $16M raised.
| Cible |
9.000.000€
|
| Minimum |
4.500€
|
| Fonds déjà levés | 2.700.000€ |
| Levées de fonds précédentes | s.o. |
| Stade de développement | Autre |
| Rôle de l'investisseur | Passif |
location_on États-Unis
Join this international health care group expand clinics in North America. Convertible Note pays 10% interest which converts into Stock pre-IPO. Company is targeting an IPO in the US at 5X Return to Investors.
location_on États-Unis
Personalized AI coordinated care navigator Most current oncology-care models can’t effectively manage patients at home IMNA is redefining remote care monitoring to reduce preventable complications and hospital visits for cancer patients.
location_on North East, États-Unis
Portable instrument sterilizer uses no electricity, heat or water. Makes safe surgery possible for 5 billion people globally. Revenue derived from consumable sales. IP protected. 50% margins. Sales by local distribution. Exit by acquisition likely.
